Market Intel: Promising Data At ATS2018 Inflate Hopes For Endobronchial Valves And New Device-Based COPD Therapies

Chronic obstructive pulmonary disease (COPD) is a widespread, progressive lung disease for which pulmonologists in the US have had few new treatment options available outside the standard pharmacological therapies, lung rehabilitation and high-risk lung volume reduction surgery. Now emerging technologies, in particular, endobronchial valves, which aim to shrink hyperinflated lungs in severe emphysema patients, could soon become the first minimally invasive treatment option available in the US. New study results, presented at this year's annual American Thoracic Society International Conference in San Diego, helped built momentum among US-based clinicians to extend upon their therapeutic arsenal for patients for devices that have already been widely used in Europe. This article discusses study findings presented at ATS, including a new cost-comparison analysis for treating COPD patients at home using non-invasive ventilation and oxygen therapy. We'll also discuss the latest innovative technologies for COPD patients presented at ATS and provide insights from leading experts on factors they think will drive treatment options forward.

COPD awareness frame poster with lungs filled with air bubbles on red background. Chronic obstructive pulmonary disease symbol. Medical template for clinics and centers. Vector illustration.

Chronic obstructive pulmonary disease, or COPD, which is a progressive lung disease characterized by the obstruction of air flow, hyperinflation and reduced gas exchange, affects some 64 million people globally and is the third leading cause of death worldwide, according to the World Health Organization.

In the US, about 11 million people are diagnosed with COPD, and roughly 3

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Respiratory

Anglonordic 25: Pictura Bio’s One-Minute Pathogen-Identifying Diagnostic Test

 

“Infectious disease should be treated in the community, not in hospitals,” Alex Batchelor, Pictura Bio CEO, told Medtech Insight at the Anglonordic Life Science Conference on 3 April in London.

LSI 2025: Intuitive Surgical CEO Gary Guthart On da Vinci 5’s Force Feedback, Digital Coaching, ION Expansion, And Robotic Surgery’s Future

 
• By 

Medtech Insight sat down with Intuitive Surgical CEO Gary Guthart at the recent LSI USA conference to discuss the full launch of the new da Vinci 5 robotic system and planned digital enhancements. Guthart also offered his views on health care interoperability, AI regulation, outpatient surgeries, autonomous robots, and how the company is harnessing technology to shape the future of robotic surgery.

Owlstone Medical Develops P.aeruginosa Breath Test For Cystic Fibrosis Patients

 

Cambridge, UK-based breath biopsy company Owlstone Medical will apply its volatile organic compound analysis platform in an attempt to develop a test for the identification and monitoring of pseudomonas aeruginosa in patients with cystic fibrosis.

Recall Alerts For Boston Scientific, Philips, J&J, And More

 
• By 

The US FDA has announced seven device safety actions in recent days. The most serious, which relates to a manufacturing defect in Boston Scientific’s Accolade pacemaker, has been linked to 832 injuries and two deaths.

More from Device Area

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By 

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

Digital Health And AI Tools Advance Cardiac Event Prediction, SCAI 2025 Data Show

 
• By 

Out-of-hospital cardiac arrest remains one of the most challenging and resource-intensive emergencies in cardiovascular care. At SCAI 2025, clinicians presented a novel algorithm that improved triage decisions and reduced unnecessary interventions.

SpotitEarly Raised $20.3M In New Funding To Bring AI- And Dog-Sniffing-Powered Early Cancer Detection Test To US

 
• By 

Israeli-based SpotitEarly hopes to bring an early cancer-detection test, which uses dogs’ noses to detect compounds in exhaled breath and AI analysis, to US homes in 2026.